For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
The Sensations – Let Me In, an upbeat number from the swingin early 60’s oldies post- doo wop era. Please enjoy more of the best…
Objective: Amyotrophic lateral sclerosis (ALS) is an incurable, progressive neurodegenerative disease with a significant health burden and poorly understood etiology. This analysis assessed the nar…
Tending to the well-being of loved ones who might fill caregiving roles, especially at vulnerable young ages, is an investment in the well-being of society…
Approximately 31,000 people are living with amyotrophic lateral sclerosis (ALS) in the United States, with an average of 5,000 new cases every year, according to…
Researchers successfully used a brain-computer interface to synthesize speech directly from brain activity in an ALS patient, achieving 80% word recognition accuracy by listeners, showcasing…
The FDA would only withdraw a rare disease gene therapy for “pretty clear” reasons, such as when there is minimal benefit with extensive side effects.…
This very special event will celebrate NORD’s legacy and achievements, and honor those individuals and organizations doing remarkable work on behalf of the rare disease…
After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert…
Please join Rep. Quigley and the ALS Caucus Co-Chairs, Reps. Calvert, Crow, Fitzpatrick, and Sewell, for an event highlighting research and care for ALS. ALS…
Obesity researchers and companies turn toward helping people maintain losses.